Screener
Axsome Therapeutics AXSM Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 254,560 | 178,445 |
| Loss from operations | (63,357) | (56,982) |
| Interest expense, net | (1,185) | (2,431) |
| Loss before income taxes | (64,542) | (59,413) |
| Income tax expense | — | — |
| Net loss | $(64,542) | $(59,413) |
| Net loss per common share, basic and diluted | $(1.26) | $(1.22) |
| Weighted average common shares outstanding, basic and diluted | 51,198,349 | 48,871,163 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's pre-tax income?
- Axsome Therapeutics (AXSM) reported pre-tax income of -$64.54M in Q1 2026.
- How has Axsome Therapeutics's pre-tax income changed year-over-year?
- Axsome Therapeutics's pre-tax income decreased by 8.6% year-over-year, from -$59.41M to -$64.54M.
- What is the long-term trend for Axsome Therapeutics's pre-tax income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's pre-tax income has grown at a 8.9% compound annual growth rate (CAGR), from -$130.4M to -$183.7M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Axsome Therapeutics's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude